Cilostazol
| Clinical data | |
|---|---|
| Pronunciation | /sɪˈlɒstəzɒl/ sil-OS-tə-zol |
| Trade names | Pletal |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601038 |
| License data |
|
| Routes of administration | By mouth (tablets) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 95–98% |
| Metabolism | Liver (CYP3A4- and CYP2C19-mediated) |
| Elimination half-life | 11–13 hours |
| Excretion | Kidney |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.215.897 |
| Chemical and physical data | |
| Formula | C20H27N5O2 |
| Molar mass | 369.469 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Cilostazol, sold under the brand name Pletal among others, is a medication used to help the symptoms of intermittent claudication in peripheral vascular disease.[1] If no improvement is seen after 3 months, stopping the medication is reasonable.[2] It may also be used to prevent stroke.[1] It is taken by mouth.[1]
Common side effects include headache, diarrhea, dizziness, and cough.[1] Serious side effects may include decreased survival in those with heart failure, low platelets, and low white blood cells.[1] Cilostazol is a phosphodiesterase 3 inhibitor which works by inhibiting platelet aggregation and dilating arteries.[1]
Cilostazol was approved for medical use in the United States in 1999.[1] It is available as a generic medication.[2] In 2019, it was the 347th most commonly prescribed medication in the United States, with more than 800 thousand prescriptions.[3]
- ^ a b c d e f g "Cilostazol Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 23 March 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 231–232. ISBN 9780857113382.
- ^ "Cilostazol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.